Alpha Teknova Inc(TKNO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:48 PM ET (Korea 9/12 08:48)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.31 | Insider Own | 79.76% | Shs Outstand | 53.7M | Perf Week | -7.32% |
| Market Cap | 0.36B | Forward P/E | - | EPS next Y | 12.96% | Insider Trans | - | Shs Float | 10.9M | Perf Month | -9.2% |
| Enterprise Value | 0.37B | PEG | - | EPS next Q | -0.07 | Inst Own | 16.97% | Short Float | 14.28% | Perf Quarter | 52.5% |
| Income | -0.02B | P/S | 8.24 | EPS this Y | 4.84% | Inst Trans | 4.45% | Short Ratio | 7.35 | Perf Half Y | 151.31% |
| Sales | 0.04B | P/B | 5.75 | EPS next 5Y | 15.57% | ROA | -16.25% | Short Interest | 1.55M | Perf YTD | 76.58% |
| Book/sh | 1.17 | P/C | 20.66 | EPS past 3/5Y | 42.42% - | ROE | -24.19% | 52W High | -14.41% ($7.84) | Perf Year | 50.11% |
| Cash/sh | 0.32 | P/FCF | - | Sales past 3/5Y | -0.73% 5.3% | ROIC | -19.04% | 52W Low | 251.31% ($1.91) | Perf 3Y | 272.78% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 23.08% | Gross Margin | 31.97% | Volatility(W/M) | 5.54% 6.75% | Perf 5Y | -70.61% |
| Dividend TTM | - | EV/Sales | 8.47 | Sales Y/Y TTM | 12.27% | Oper. Margin | -35.08% | ATR (14) | 0.43 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.48 | EPS Q/Q | 11.53% | Profit Margin | -38.37% | RSI (14) | 48.03 | Recom | 1.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.49 | Sales Q/Q | 18.45% | SMA20 | -5.92% ($7.13) | Beta | 0.89 | Target Price | $8.6 |
| Payout | - | Debt/Eq | 0.44 | Earnings | 2026/8/5 | SMA50 | 7.83% ($6.22) | Rel Volume | 0.47 | Prev Close | $6.91 |
| Employees | 158 | LT Debt/Eq | 0.41 | EPS/Sales Surpr. | 28.83% 11.26% | SMA200 | 57.47% ($4.26) | Avg Volume(3M) | 0.21M | Price | $6.71 |
| IPO | 2021/6/25 | Option/Short | Yes/Yes | Trades | 1984 | Volume | 99,954 | Change | -2.89% |
Company
TKNO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧪 This is a US specialty reagent manufacturer that supplies custom life-science reagents and media used in cell and gene therapy as well as new drug research and production. Headquartered in the US, it has built a broad base of early-stage biotech customers by leveraging fast delivery and small-batch custom manufacturing as its competitive edge, and is classified as a micro-cap stock.
Over the past 1 year, on the higher side
14% below its 1-year high.
TKNO has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +4.8% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +272.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 17.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
TINY 0.00%
IBBQ 0.00%
BIB 0.00%
IWC 0.00%
IBB 0.00%It ranks #4 in the industry
Based on market cap of $360M.
TKNO $360M PER -
TAK $58B PER -
TEVA $43B PER 62.4
HLN $40B PER 18.9
FAQ
What kind of company is TKNO?
TKNO belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of TKNO?
The market cap of TKNO is approximately $360M, ranking 3,521 within its sector.
What is the 52-week high and low for TKNO?
TKNO has recorded a 52-week high of $7.84 and a low of $1.91.
